Original document(9 pages)  中文版
    The present invention is one kind of medicine composition for treating tumor and cardiac and cerebral vascular diseases and the composite medicine contains Prostaglandin E1, ribonucleic acid, aspirin or aspirin-DL-lysine and reductive glutathione. The medicine may be prepared into various forms, and has obvious clinical curative effect. The medicine composition can be used to treat both tumor and cardiac and cerebral vascular diseases and has less side effect and adverse reaction.
Application Number
申请号		 02121399 Application Date
申请日		 2002.06.19
Title 名称 Medicine composition for treating tumor and cardiac and cerebral vascular diseases
Publication Number
公开号		 1398592 Publication Date
公开日		 2003.02.26
Approval Pub. Date Granted Pub. Date
International Classification 分类号 A61K31/7088,A61P9/10,A61P35/00
Applicant(s) Name
申请人		 Cai Haide
Address 地址 330009
Inventor(s) Name 发明人
Attorney & Agent 代理人 zhang rehua
More information 更  多  信  息


 Related patents information
Compound recipe formula containing kurarinone prostaglandin E1 and aspirin, its preparation method and application
Compound prepn containing prostaglandin E1, prostaglandin A1 and prostaglandin B1 and its prepn process and use
Aseptic freeze-dried prostaglandin injection and its preparing method and use
Piracetam medicine composition with function of promoting thinking and memory and its prepn
Thymosin composition injection and its prepn
Medicine for preventing and treating infectious diseases caused by virus, e.g. SARS
Compound preparation for preventing and treating typical model pneumonia and other virus infection diseases
Prostaglandin E1 medicine material and its production technology
Production technology of material medicine for prostaglandin E1
Preparation of bacteria-free freezing-dried prostaglandin E1 powder injection
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.